Doorbell video surveillance company Ring was purchased by Amazon Inc. (AMZN)  , with some reports saying the value of the deal was about $1 billion. 

Ring joins Amazon's portfolio of other camera products, including the Echo Look fashion-advice camera and the Amazon Cloud Cam indoor security camera. Amazon now has ready-made products for surveillance inside and outside of the home, and the market has noticed.

Action Alerts Plus holding Amazon unveiled Cloud Cam in October, announcing the device had a $119.99 price tag. 

Home security companies Alarm.com Holdings Inc.  (ALRM) and ADT Inc. (ADT)  fell 5.3% and 8.9%, respectively, in trading on Wednesday. Amazon shares rose slightly. 

Amazon purchased another smart camera company, Blink, reportedly for $90 million in December, but that purchase was seen as a conduit for the company to have access to battery lengthening technology. Ring, on the other hand, has a product that is already popular with the public. 

Ring's devices currently integrate with Amazon's home assistant Alexa. 

"Ring is committed to our mission to reduce crime in neighborhoods by providing effective yet affordable home security tools to our neighbors that make a positive impact on our homes, our communities, and the world," a Ring spokesperson said in a statement. "We'll be able to achieve even more by partnering with an inventive, customer-centric company like Amazon. We look forward to being a part of the Amazon team as we work toward our vision for safer neighborhoods."

More from Technology

Why Jim Cramer Is Holding Off on Buying Nvidia Stock

Why Jim Cramer Is Holding Off on Buying Nvidia Stock

Why Netflix Is Revealing More Viewership Numbers Now

Why Netflix Is Revealing More Viewership Numbers Now

Cisco Is 'Underappreciated', Poised to Gain from Huawei Scrutiny: JPMorgan

Cisco Is 'Underappreciated', Poised to Gain from Huawei Scrutiny: JPMorgan

3 Things to Know at Market Close: Netflix, Chinese New Year, and KPMG

3 Things to Know at Market Close: Netflix, Chinese New Year, and KPMG

Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial

Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial